BIOMAT Database Logo BIOMAT Database Logo

[The prolonged-action form of Lomir (isradipine) in the treatment of mild and moderate essential hypertension]. 1996

V V Dmitriev, and G G Arabidze, and O N Epifanova, and A N Rogoza, and T V Metelitsa, and V B Mychka

24-hour monitoring of arterial pressure has been performed outpatiently in 20 subjects with mild or moderate essential hypertension using portable system Space Labs 90207. The design of the study implied 2 weeks of observation without any treatment followed by a 4-week course of lomir SRO-5 plus a 2-week course of lomir administration in a double dose. Control examination was performed at the end of each period. It was established that a 4-week lomir course results in a lowering of systolic and diastolic pressure by 8.4 + -2.1 and 6.9 + -1.3 mm Hg, respectively. Double-dose lomir was also effective: a fall in both systolic and diastolic pressure by 15.6 + -3.2 and 8.1 + -1.8 mm Hg, respectively, was achieved.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive

Related Publications

V V Dmitriev, and G G Arabidze, and O N Epifanova, and A N Rogoza, and T V Metelitsa, and V B Mychka
Isradipine in the treatment of mild to moderate essential hypertension.
October 1991, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
V V Dmitriev, and G G Arabidze, and O N Epifanova, and A N Rogoza, and T V Metelitsa, and V B Mychka
Isradipine (Lomir) in the treatment of hypertension. Introduction.
January 1990, Cor et vasa,
V V Dmitriev, and G G Arabidze, and O N Epifanova, and A N Rogoza, and T V Metelitsa, and V B Mychka
[The calcium antagonist isradipine (Lomir) in the treatment of patients with essential hypertension].
January 1992, Terapevticheskii arkhiv,
V V Dmitriev, and G G Arabidze, and O N Epifanova, and A N Rogoza, and T V Metelitsa, and V B Mychka
The antihypertensive action of isradipine in mild essential hypertension.
January 1991, Journal of cardiovascular pharmacology,
V V Dmitriev, and G G Arabidze, and O N Epifanova, and A N Rogoza, and T V Metelitsa, and V B Mychka
Efficacy, tolerability and safety of isradipine (Lomir) in the treatment of mild to moderate Tanzanian hypertensives.
December 1992, East African medical journal,
V V Dmitriev, and G G Arabidze, and O N Epifanova, and A N Rogoza, and T V Metelitsa, and V B Mychka
Isradipine in the treatment of mild-to-moderate hypertension in Portugal.
January 1992, Journal of cardiovascular pharmacology,
V V Dmitriev, and G G Arabidze, and O N Epifanova, and A N Rogoza, and T V Metelitsa, and V B Mychka
Metabolic, hematological, and cardiac effects of long-term isradipine treatment in mild-to-moderate essential hypertension.
January 1992, Journal of cardiovascular pharmacology,
V V Dmitriev, and G G Arabidze, and O N Epifanova, and A N Rogoza, and T V Metelitsa, and V B Mychka
Isradipine in the treatment of mild-to-moderate hypertension in geriatric patients.
July 1994, American journal of hypertension,
V V Dmitriev, and G G Arabidze, and O N Epifanova, and A N Rogoza, and T V Metelitsa, and V B Mychka
[Clinical trial with isradipine in the treatment of mild and moderate arterial hypertension].
December 1991, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology,
V V Dmitriev, and G G Arabidze, and O N Epifanova, and A N Rogoza, and T V Metelitsa, and V B Mychka
Isradipine in the treatment of mild-to-moderate hypertension. The Austrian Multicenter Isradipine cum Spirapril Study (AMICUS).
March 1993, American journal of hypertension,
Copied contents to your clipboard!